BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protective protein isolated from human gastric juice. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Decades of preclinical work — primarily from Sikiric and colleagues at the University of Zagreb — document a broad regenerative profile spanning tendon, ligament, muscle, gut epithelium, bone, and neural tissue.
VEGF-Driven Angiogenesis
Angiogenesis is rate-limiting for tissue repair: without adequate blood supply, fibroblast proliferation and collagen deposition stall. In rodent injury models, BPC-157 has been reported to recruit blood vessels toward perforating defects and to activate collateral vessels that bypass an occluded vein (Sikiric et al., 2018, Current Pharmaceutical Design).
FAK-Paxillin Pathway and Cell Migration
In cultured rat Achilles tendon fibroblasts, Chang et al. reported increased phosphorylation of focal adhesion kinase (FAK) and paxillin, together with increased cell migration and spreading. That experiment examined tendon fibroblasts in vitro and tendon explant outgrowth ex vivo; it did not measure wound closure or scar formation.
GH Receptor Upregulation
BPC-157 appears to sensitize tissue to growth hormone signaling by upregulating GH receptor expression locally, amplifying downstream IGF-1 production and anabolic remodeling at the injury site. This may explain why its effects appear organ-local rather than systemic.
Gut and Mucosal Protection
The cited Sikiric review discusses BPC-157 and mucosal integrity in preclinical gastrointestinal injury models, including stomach perforation and venous occlusion. Its abstract describes vascular recruitment and re-established blood flow; it does not establish a gut-brain neurotransmitter mechanism.
Tendon and Ligament Models
Gwyer et al. review predominantly small-rodent studies of tendon, ligament, and skeletal-muscle injury. Chang et al. examined rat tendon explants and cultured tendon fibroblasts; those experiments did not measure biomechanical strength or scar formation.
Research Status
The BPC-157 evidence base is overwhelmingly preclinical. The cited 2019 review describes evidence that was predominantly from small rodents, with human findings still unconfirmed. That preclinical evidence does not establish a human safety profile. It is sold exclusively as a research compound for laboratory use only.
Related research compound:
BPC-157 — View Product Page →References
- Sikiric P, et al. (2018). Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing. Current Pharmaceutical Design, 24(18), 1990–2001.
- Chang CH, et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol, 110(3), 774–780.
- Gwyer D, et al. (2019). Gastric pentadecapeptide BPC 157 and musculoskeletal soft tissue healing. Cell Tissue Res, 377(2), 153–159.
This article summarizes publicly available research for educational purposes and does not constitute medical advice, a therapeutic claim, or a recommendation for human use. Products referenced are sold for laboratory research use only.